Literature DB >> 31813753

Strong toll-like receptor responses in cystic fibrosis patients are associated with higher lung function.

Susanna Kosamo1, Katherine B Hisert1, Victoria Dmyterko1, Catherine Nguyen1, R Anthony Black2, Tarah D Holden1, Frank Radella1, Pauline A Cotten1, Christopher H Goss1, Moira L Aitken1, Mark M Wurfel3.   

Abstract

BACKGROUND: Cystic fibrosis (CF) airways disease varies widely among patients with identical cystic fibrosis transmembrane conductance regulator (CFTR) genotypes. Robust airway inflammation is thought to be deleterious in CF; inter-individual variation in Toll-like receptor (TLR)-mediated innate immune inflammatory responses (TMIIR) might account for a portion of the phenotypic variation. We tested if TMIIR in people with CF are different than those of healthy controls, and whether higher TMIIR in people with CF are associated with reduced lung function.
METHODS: We cultured whole blood from clinically stable subjects with CF (n = 76) and healthy controls (n = 45) with TLR agonists, and measured cytokine production and expression of TLR-associated genes. We tested for differences in TLR-stimulated cytokine levels between subjects with CF and healthy subjects, and for associations between cytokine and gene expression levels with baseline lung function (forced expiratory volume in one second percent predicted (FEV1%)) and decline in FEV1% over time.
RESULTS: TMIIR in blood from subjects with CF were lower than in healthy controls. Expression of TLR regulators SARM1, TOLLIP, and AKT1 were downregulated in CF. In subjects with CF we found that lower TLR4-agonist-induced IL-8 was associated with lower FEV1% at enrollment (p<0.001) and with greater five year FEV1% decline (p<0.001).
CONCLUSIONS: TMIIR were lower in people with CF relative to healthy controls; however, unexpectedly, greater whole blood TMIIR were positively associated with lung function in people with CF. These findings suggest a complex interaction between inflammation and disease in people with CF.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Cystic fibrosis; Innate Immunity; Respiratory function tests; Toll-like receptors

Year:  2019        PMID: 31813753      PMCID: PMC7272272          DOI: 10.1016/j.jcf.2019.11.009

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  18 in total

1.  Statistical significance for genomewide studies.

Authors:  John D Storey; Robert Tibshirani
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-25       Impact factor: 11.205

2.  Cystic Fibrosis Plasma Blunts the Immune Response to Bacterial Infection.

Authors:  Xi Zhang; Amy Pan; Shuang Jia; Justin E Ideozu; Katherine Woods; Kathleen Murkowski; Martin J Hessner; Pippa M Simpson; Hara Levy
Journal:  Am J Respir Cell Mol Biol       Date:  2019-09       Impact factor: 6.914

3.  The influence of genetics on cystic fibrosis phenotypes.

Authors:  Michael R Knowles; Mitchell Drumm
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

4.  Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungs.

Authors:  Nicholas W Keiser; Susan E Birket; Idil A Evans; Scott R Tyler; Adrianne K Crooke; Xingshen Sun; Weihong Zhou; Joseph R Nellis; Elizabeth K Stroebele; Kengyeh K Chu; Guillermo J Tearney; Mark J Stevens; J Kirk Harris; Steven M Rowe; John F Engelhardt
Journal:  Am J Respir Cell Mol Biol       Date:  2015-06       Impact factor: 6.914

5.  Effect of high-dose ibuprofen in patients with cystic fibrosis.

Authors:  M W Konstan; P J Byard; C L Hoppel; P B Davis
Journal:  N Engl J Med       Date:  1995-03-30       Impact factor: 91.245

6.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

Authors:  Julia Emerson; Margaret Rosenfeld; Sharon McNamara; Bonnie Ramsey; Ronald L Gibson
Journal:  Pediatr Pulmonol       Date:  2002-08

7.  Translocated LPS might cause endotoxin tolerance in circulating monocytes of cystic fibrosis patients.

Authors:  Rosa del Campo; Eriel Martínez; Carlos del Fresno; Raquel Alenda; Vanesa Gómez-Piña; Irene Fernández-Ruíz; María Siliceo; Teresa Jurado; Victor Toledano; Francisco Arnalich; Francisco García-Río; Eduardo López-Collazo
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

8.  Pseudomonas aeruginosa LPS or flagellin are sufficient to activate TLR-dependent signaling in murine alveolar macrophages and airway epithelial cells.

Authors:  Eloïse Raoust; Viviane Balloy; Ignacio Garcia-Verdugo; Lhousseine Touqui; Reuben Ramphal; Michel Chignard
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

9.  Monocytes from cystic fibrosis patients are locked in an LPS tolerance state: down-regulation of TREM-1 as putative underlying mechanism.

Authors:  Carlos del Fresno; Vanesa Gómez-Piña; Vanesa Lores; Alessandra Soares-Schanoski; Irene Fernández-Ruiz; Blas Rojo; Rodolfo Alvarez-Sala; Ernesto Caballero-Garrido; Felipe García; Tania Veliz; Francisco Arnalich; Pablo Fuentes-Prior; Francisco García-Río; Eduardo López-Collazo
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

10.  Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population.

Authors:  Deepika Polineni; Annalisa V Piccorelli; William B Hannah; Sarah N Dalrymple; Rhonda G Pace; Peter R Durie; Simon C Ling; Michael R Knowles; Jaclyn R Stonebraker
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240

View more
  1 in total

1.  CFTR Modulator Therapy Enhances Peripheral Blood Monocyte Contributions to Immune Responses in People With Cystic Fibrosis.

Authors:  Katherine B Hisert; Timothy P Birkland; Kelly Q Schoenfelt; Matthew E Long; Brenda Grogan; Suzanne Carter; W Conrad Liles; Edward F McKone; Lev Becker; Anne M Manicone; Sina A Gharib
Journal:  Front Pharmacol       Date:  2020-08-13       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.